Innovative Treatment Platform PanTher Therapeutics has developed the proprietary Sagittari™ platform for localized, high-dose cancer treatments, creating opportunities to offer specialized delivery devices, formulation services, and compatible drug products to enhance integrated oncology treatment solutions.

Strategic Funding & Growth With recent grants totaling over 19 million dollars and a Series A funding of 5.4 million, the company demonstrates strong investor confidence and active development, paving the way for potential partnerships in clinical research support and biotechnology infrastructure expansion.

Expanding Presence The company's recent relocations and office expansion in Texas indicate growth and a focus on regional partnerships, offering opportunities to engage with local research institutes, clinical trial providers, and healthcare facilities for collaborative development and distribution.

Market Focus & Indications PanTher is targeting solid tumor indications such as pancreatic cancer, with plans to explore additional cancers, providing a route for sales in specialty therapeutic formulations, localized delivery devices, and companion diagnostics tailored to oncology specialists.

Leadership & Strategic Growth Recent leadership appointments, including an Executive Chair, highlight a focus on strategic positioning, offering a gateway for executive-level networking, partnership development, and potential co-investment opportunities in innovative oncology treatments.